What is the long-term trend for Aquestive Therapeutics, Inc.'s allowance for credit losses?

Over 2 years (2023 to 2025), Aquestive Therapeutics, Inc.'s allowance for credit losses has grown at a 56.2% compound annual growth rate (CAGR), from $73K to $178K.

What does allowance for credit losses mean?

Reserve held against the loan portfolio for estimated future credit losses under the CECL methodology — a contra-asset reducing net loans.

Aquestive Therapeutics, Inc. AQST Allowance for credit losses

Allowance for credit losses at other companies

Aurinia PharmaceuticalsAUPH

$378.95M+21.1%

Other financials

Income statement

See full

Revenue$14.4M+65.7%

Gross profit$11.0M+117%

Operating income-$4.2M+78.3%

Net income-$8.1M+64.9%

EPS (diluted)-$0.07+70.8%

Balance sheet

See full

Cash & equivalents$110.7M+61.3%

Total debt$64.4M+7.4%

Total equity-$34.1M+44.1%

Total assets$141.1M+38.0%

Cash flow

See full

Operating cash flow-$14.8M+36.7%

CapEx$52.0K-61.5%

Free cash flow-$14.9M+36.9%

Valuation

See full

Market cap$560.13M+73.5%

Enterprise value$513.76M+63.6%

P/S11.1×+5.2×

Profitability

See full

Gross margin63.5%-4.9pp

Operating margin-111.2%+96.3pp

Net margin-137.1%+80.7pp

FCF margin-88.2%-2.2pp

Returns & leverage

See full

Return on equity145.1%—

Debt / equity-1.9×—

Current ratio4.1×-0.8×

Where this comes from

Reported directly by Aquestive Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals.

The official record: Aquestive Therapeutics, Inc.’s 10-K, filed March 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Aquestive Therapeutics, Inc.'s allowance for credit losses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Aquestive Therapeutics, Inc.'s allowance for credit losses?: Aquestive Therapeutics, Inc. (AQST) reported allowance for credit losses of $178K in Q4 2025.
What is the long-term trend for Aquestive Therapeutics, Inc.'s allowance for credit losses?: Over 2 years (2023 to 2025), Aquestive Therapeutics, Inc.'s allowance for credit losses has grown at a 56.2% compound annual growth rate (CAGR), from $73K to $178K.
What does allowance for credit losses mean?: Reserve held against the loan portfolio for estimated future credit losses under the CECL methodology — a contra-asset reducing net loans.